Irfan A Asangani

4PUBLICATIONS
28CO-AUTHORS
Molecular targetsPredictive and prognostic markersTissue engineering
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jun 12, 2025
The H3 K36M oncohistone inhibits NSD2 to activate a SETD2-dependent antiviral-like immune response in KRAS-driven lung cancer.

Amy C Gladstein, Carson D Poltorack, Akino Mercy Charles Solomon

|Sep 09, 2024
NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis.

Abhijit Parolia, Sanjana Eyunni, Brijesh Kumar Verma

|Feb 26, 2024
Cellular reprogramming in vivo initiated by SOX4 pioneer factor activity.

Takeshi Katsuda, Jonathan H Sussman, Kenji Ito

|Aug 29, 2023
Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance.

Reyaz Ur Rasool, Caitlin M O'Connor, Chandan Kanta Das

Pageof 1